Amgen (AMGN) Debt to Equity (2009 - 2026)

Amgen (AMGN) has reported Debt to Equity for 18 consecutive years, with $6.24 the latest figure, recorded in Q1 2026.

• In Q1 2026, Debt to Equity fell 32.53% year-over-year to $6.24; the TTM figure through Mar 2026 stood at $6.24 (down 32.53% YoY), while the FY2025 annual figure was $6.31, down 38.33% from the prior year.
• Debt to Equity came in at $6.24 for Q1 2026 at Amgen, down from $6.31 in the prior quarter.
• The five-year high for Debt to Equity was $40.23 in Q1 2022, with the low at $5.67 in Q3 2025.
• Average Debt to Equity over 5 years is $11.3, with a median of $10.23 recorded in 2024.
• Across the five-year window, Debt to Equity jumped 1048.97% in 2022 and plunged 71.37% in 2023, its largest moves.
• Year by year, Debt to Equity stood at $10.64 in 2022, then slipped by 2.54% to $10.37 in 2023, then retreated by 1.37% to $10.23 in 2024, then slumped by 38.33% to $6.31 in 2025, then decreased by 1.1% to $6.24 in 2026.
• According to Business Quant data, Debt to Equity over the past three periods registered $6.24, $6.31, and $5.67 for Q1 2026, Q4 2025, and Q3 2025 respectively.